title: Future prospects in immunosuppression for liver transplantation.
abstract: 1. Our increasing understanding of signaling pathways and cellular interactions in transplant immunobiology and the availability of novel immunosuppressive agents have facilitated targeted strategies. 2. The driving forces behind the development of new immunosuppressive regimens are the long-term complications of current immunosuppressive regimens (particularly renal dysfunction and metabolic disturbances). 3. By regulatory mandate, the requirement for the primary endpoint to be a composite of death, graft loss, and rejection remains intact; however, current and future clinical trials could incorporate key secondary endpoints that address renal and metabolic derangements.
authors.affiliation: Digestive Disease Institute, Cleveland Clinic, Cleveland, OH 44195, USA. fungj@ccf.org
authors.forename: John J
authors.initials: JJ
authors.lastname: Fung
authors.forename: Jessica E
authors.initials: JE
authors.lastname: Bollinger
authors.forename: Charles
authors.initials: C
authors.lastname: Miller
authors.forename: Bijan
authors.initials: B
authors.lastname: Eghtesad
mesh_terms: D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000639:trends*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000639:trends*
chemical_list: D007166:Immunosuppressive Agents